# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-24 (automated review run)
**Prepared by:** Hub Monitor (scheduled task)
**Scope:** Read-only review of `Analysis/Results/` outputs + web scan. No existing files modified.

---

## TL;DR — The thing you don't want to hear

**The data pipeline has now been frozen for a full week and this report can add almost nothing new since 07-23.** Clinical-trials and PubMed snapshots are still stuck at **2026-07-17** — now **7 days old**. The last three monitor runs (07-21, 07-22, 07-23) all flagged the same staleness, and nothing has changed: `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` have not run since 07-17. The gap analysis *did* refresh (report 07-23, data 07-18), so the literature arm is alive — but your trial/PubMed intelligence is running blind on a week-old fetch while three tracked therapies had real regulatory/data events. **A "no change" signal from this monitor is currently meaningless: the scripts that would detect change never ran.** [Certain — file mtimes and identical 07-21→07-23 diffs confirm it]

The single action that matters this week: run the two baseline fetch scripts. Everything else is noise until you do.

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 7 days | ⚠️ Stale |
| `pubmed_recent_latest.json` | 2026-07-17 | 7 days | ⚠️ Stale |
| `hub_monitor_report.md` | 2026-07-17 | 7 days | ⚠️ Stale (no scan 07-18 → 07-24) |
| `literature_gap_report.md` | 2026-07-23 | 1 day | ✅ Fresh |
| `literature_gap_data.json` | 2026-07-18 | 6 days | ◐ Aging |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 7 days | ◐ Aging |
| Latest trial snapshot | `..._2026-07-17.json` | 7 days | ⚠️ No snapshot 07-18 → 07-24 |
| Latest PubMed snapshot | `..._2026-07-17.json` | 7 days | ⚠️ No snapshot 07-18 → 07-24 |

`agent_state.json` continues to update daily (last backup 07-23), so the agent loop itself is healthy. The failure is isolated to the **data-refresh scripts**, which have not executed for 7 days. The hub's own review flag reports **827 result files older than 14 days**. This is a scheduling/cron gap, not a transient miss. [Certain]

---

## Clinical Trial Changes

No new fetch since 07-17, so there is **no new movement to report** beyond what the 07-17 → 07-23 runs already covered. Figures below are all from the **07-17 snapshot** (858 trials).

**Category counts (07-17 snapshot):** T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies (P2-3) 147 · Diabetes Technology 236 · Recently Completed w/ Results 321.

**Week-over-week drift captured in the snapshot (07-10 → 07-17):** 6 net-new trial records, 2 removed. The genuinely new *research-stage* additions were:

- **NCT07699380** — Univ. of Washington, **MetMod-T1D**, Phase 2 RECRUITING — metabolic modulation to improve insulin sensitivity/mitochondrial function in T1D.
- **NCT07702890** — Gubra A/S, **GUB-UCN2** Phase 1/2, NOT_YET_RECRUITING — first-in-human urocortin-2 analog in T2D/obesity.
- **NCT07696273** — Indiana Univ., breath-based hypo/hyperglycemia sensor, RECRUITING (device).
- The rest (NCT05086445, NCT05254002, NCT05574699, NCT04717050) were COMPLETED records surfacing with newly posted results, not new studies.

**Key Phase 3 RECRUITING trials — priority sponsors (from 07-17 snapshot; 52 P3 trials RECRUITING total):**

| NCT | Sponsor | Asset | Status |
|-----|---------|-------|--------|
| NCT06832410 / NCT04786262 | Vertex | VX-880 (zimislecel) — incl. kidney-transplant cohort | RECRUITING (P3) |
| NCT07222332 / NCT07222137 | Eli Lilly | Baricitinib — BARICADE-PRESERVE / Stage-3 delay | RECRUITING (P3) |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) in T1D | RECRUITING (P3) |
| NCT07564414 | Novo Nordisk | CagriSema | RECRUITING (P3) |
| NCT07088068 | Sanofi | Teplizumab vs placebo, stage-3 T1D | RECRUITING (P3) |
| NCT07662135 / 662044 | AstraZeneca | Elecoglipron (T2D + renal) | RECRUITING (P3) |

**Recently posted results worth reviewing** (from snapshot, newest first): NCT05086445 (Lilly orforglipron PK, Japanese pts, 07-16); NCT05574699 (JHU social-risk CDS closed-loop referral, 07-15); NCT05254002 (Bayer finerenone + empagliflozin in CKD/T2D, P2, 07-13); NCT03263494 (Jaeb CGM in teens/young adults T1D, 07-09); NCT04255433 (Lilly tirzepatide vs dulaglutide CV outcomes, P3, 07-08).

*Nothing above is new versus the 07-23 report. It cannot be until the fetch script runs.* [Certain]

---

## PubMed Highlights

From `pubmed_recent_latest.json` (07-17; 158 unique papers over a 30-day lookback, 16 domains, 8 tracked therapies). **12 cross-domain papers** (the highest-value class). Most notable:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — spans **AI/ML + Closed-Loop AP + Health Equity** (3 domains). Directly on a Tier-1 axis (AI/ML) intersecting an under-researched equity domain. Worth a read.
- **[42419792]** *Comparative effects of drugs for overweight/obesity: network meta-analysis* — orforglipron + retatrutide + CagriSema in one analysis (3 tracked therapies).
- **[42458730]** & **[42459212]** — Microbiome × Multi-Omics (multi-omic BMI-response modelling; precision-nutrition multi-omics review). Both sit on **Tier-1 Multi-Omics Biomarker Integration**.
- **[42453334]** — Biomarker × LADA (ncRNAs for diabetes); **[42411999]** — Stem-Cell Cure × Immunotherapy (T1D from residual recipient T cells post-HCT, case report).

**Tracked-therapy signal (paper counts):** dapagliflozin 5 · orforglipron 5 · CagriSema 5 · retatrutide 4 · teplizumab 4 · icodec 3 · baricitinib 2 · **zimislecel 0**. Zimislecel (VX-880) has had zero indexed papers in the lookback window despite two active Vertex Phase 3s — a publication gap worth watching once the pipeline refreshes.

*This is the same 07-17 corpus reported last week; no newer PubMed pull exists.* [Certain]

---

## Gap Analysis Summary

Gap report is **fresh (07-23)**. Top under-researched intersections flagged as *potentially meaningful* (Gap Score 100 = zero joint pubs), **Validation level: BRONZE** — single analytical source, expert confirmation required:

1. **Treg / CAR-T × Neuropathy** (0 joint) — immune-mediated diabetic neuropathy as a Treg-modulation target; no bridging work.
2. **Beta Cell Regen × Health Equity** (0) — no equity analysis of who accesses emerging cell therapies.
3. **Treg / CAR-T × Health Equity** (0) — no access analysis for CAR-Treg/TCR-Treg.
4. **Glucokinase × Health Equity** (0) — no equity work on GK activators.
5. **Gene Therapy × LADA** (0) — LADA's autoimmune mechanism unexplored for gene-therapy approaches.

(Also flagged: Drug Repurposing × Health Equity, and Insulin Resistance × Islet Transplant, Gap 91.9 / 1 joint pub.)

**Alignment with Tier-1 contribution areas (RESEARCH_DOCTRINE.md):** The doctrine's Tier-1 axes are Multi-Omics Biomarker Integration, Literature Synthesis & Gap Analysis, Clinical Trial Intelligence, Drug Repurposing, and AI/ML Prediction. Two of the top gaps map cleanly onto Tier-1 **Drug Repurposing** (Drug Repurposing × Health Equity) and the cross-domain PubMed hits map onto **Multi-Omics** and **AI/ML** — meaning the freshest, most actionable intelligence you have this week is on the literature side, not the trial side. Reminder per doctrine: all gap classifications stay at BRONZE until triple-source validated; do not record above BRONZE without expert sign-off. [Certain — sourced from gap report + doctrine]

---

## Breaking News (web scan, last 7 days)

Nothing has broken in the last 24 hours that wasn't already in the 07-23 report. The three significant items remain, all on therapies you track, and **none are yet in the 07-17 snapshot**:

- **Orforglipron (Foundayo) — FDA-approved for chronic weight management.** Lilly's oral non-peptide GLP-1; approval issued under the National Priority Voucher program (reported as fastest new-molecular-entity approval since 2002). The **type-2 diabetes** indication is still in review, supported by the ATTAIN-2 / ACHIEVE Phase 3 program (beat oral semaglutide on HbA1c; more GI AEs). [Likely — Lilly IR + FDA + multiple secondary sources; confirm exact T2D filing status against primary]
- **Retatrutide — first Phase 3 T2D + obesity data (ADA 2026, June).** GIP/GLP-1/glucagon triple agonist: HbA1c −1.7 to −1.9% vs −0.8% placebo; weight −11.5% to −15.3% vs −2.6% at 40 wks; signals in OSA and knee OA pain. [Likely — ADA press release + secondary; verify vs NEJM/primary before recording above BRONZE]
- **Tzield (teplizumab) — pediatric approval**, supported by Phase 3 **PROTECT** (328 children/adolescents 8–17, recent-onset stage-3 T1D). Directly relevant to the Sanofi teplizumab P3 (NCT07088068) and the Lilly baricitinib P3s in the tracker. [Likely]

**Still unresolved — confirm on next real fetch:** Lilly **insulin efsitora alfa** (once-weekly basal, QWINT program) FDA decision for T2D was expected around this month; sources scanned show it still pending, not yet decided. Would compete directly with Novo's already-approved weekly icodec (Awiqli). [Guessing on timing — needs a targeted check]

---

## Recommended Actions

Ordered by leverage.

1. **Fix the pipeline first — run the two fetch scripts.** This is the whole game this week:
   `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py`
   Then `python hub_monitor.py` to regenerate the change diff against a real, current fetch. Until this runs, treat every "no change" in this report as unverified. [Certain]
2. **Investigate *why* the fetch stopped.** The agent loop and gap scripts run daily but the two baseline scripts have not fired since 07-17. Check the scheduler/cron entry or the script's own error log — 7 days of silent failure means no alerting is wired to these two jobs specifically. [Certain this is the failure; Guessing on root cause]
3. **On the next real fetch, confirm three regulatory items** so the tracker records them at the right evidence level: (a) orforglipron T2D indication status, (b) insulin efsitora alfa FDA decision, (c) teplizumab pediatric label. All three touch tracked assets. [Likely relevant]
4. **Read cross-domain paper [42459945]** (AI/ML × Closed-Loop × Health Equity, pediatric T1D algorithmic-discrimination framework) — it sits on a Tier-1 axis and one of the top gap intersections. Highest-value single item in the current corpus. [Likely]
5. **Note the zimislecel publication gap** (0 indexed papers vs 2 active Vertex P3s) — flag for the next PubMed pull to confirm it isn't a query/terminology artifact. [Likely]
6. **Gap classifications stay BRONZE.** Per doctrine, submit the top-5 intersections (esp. Drug Repurposing × Health Equity, which maps to Tier-1) to domain review before any are elevated. Do not record above BRONZE. [Certain]

---

*Generated by Diabetes Research Hub Monitor — automated run 2026-07-24. Read-only; no source files modified. Evidence levels per RESEARCH_DOCTRINE.md v1.0.*
